Skip to content

Trial Summary

This study aims to determine the maximum tolerated dose (MTD) and assess the efficacy of panitumumab, irinotecan and trifluridine/tipiracil when given in combination for participants with RAS/BRAF wild-type (WT) metastatic colorectal cancer (mCRC).



ACTRN/NCT /ethics:


Scientific title:

An open label dose-finding, safety and tolerability study of Panitumumab, Irinotecan, Trifluridine/Tipiracil in RAS wild-type patients with metastatic colorectal cancer.

Sponsor / Cooperative group:

The Queen Elizabeth Hospital

Trial & Patient Characteristics

Cancer TypeBowel and colon
Trial TypeTreatment
PhasePhase I; Phase II
Age Range18 years and older
Tumour Stream Colorectal cancer
Cancer StageMetastatic or Widespread
Anticipated Start Date-
Anticipated End Date-

Participating Hospitals

HospitalRoyal Adelaide Hospital
Clinical Trial CoordinatorAnne Milton
Phone08 7074 2342
Principal InvestigatorDr Nimit Singhal
Recruitment StatusRecruiting
HospitalThe Queen Elizabeth Hospital
Clinical Trial CoordinatorPamela Cooper
Phone08 8222 6140
Principal InvestigatorProfessor Tim Price
Recruitment StatusRecruiting
HospitalFlinders Medical Centre
Clinical Trial CoordinatorHannah Adelson
Phone08 8206 4835
Principal InvestigatorProfessor Chris Karapetis
Recruitment StatusRecruiting
HospitalLyell McEwin Hospital
Clinical Trial CoordinatorAndy Phay
Phone08 8282 0833
Principal InvestigatorDr Rohit Joshi
Recruitment StatusRecruiting